Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer Tekijä Malla, SB, Byrne, RM, Lafarge, MW, Corry, SM, Fisher, NC, Tsantoulis, PK, Mills, ML, Ridgway, RA, Lannagan, TRM, Najumudeen, AK, Gilroy, KL, Amirkhah, R, Maguire, SL, Mulholland, EJ, Belnoue-Davis, HL, Grassi, E, Viviani, M, Rogan, E, Redmond, KL, Sakhnevych, S, McCooey, AJ, Bull, C, Hoey, E, Sinevici, N, Domingo, E, Blake, A, Maughan, TS, Leedham, SJ, Koelzer, VH

In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer Tekijä Malla, SB, Fisher, DJ, Domingo, E, Blake, A, Hassanieh, S, Redmond, KL, Richman, SD, Youdell, M, Walker, SM, Logan, GE, Chatzipli, A, Amirkhah, R, Humphries, MP, Craig, SG, McDermott, U, Seymour, MT, Morton, DG, Quirke, P, West, NP, Salto-Tellez, M, Kennedy, RD, Johnston, PG, Tomlinson, I, Koelzer, VH, Campo, L, Kaplan, RS, Longley, DB, Lawler, M, Maughan, TS, Brown, LC, Dunne, PD